SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Heart rate variability suppression in cancer patients versus non-cancer controls: a systematic review and meta-analysis.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer-associated autonomic dysfunction may suppress heart rate variability (HRV), yet no meta-analysis has pooled between-group differences in established HRV indices across cancer types. This review quantified HRV differences versus non-cancer controls, HRV-fatigue associations, and longitudinal HRV trajectories.
methodsPubMed, MEDLINE, CINAHL, Embase, and the Cochrane Library were searched through March 2026. Adults with physician-confirmed malignancy and ECG- or PPG-based HRV were eligible. Because time-domain indices scale with recording length, the DerSimonian-Laird random-effects pool was restricted a priori to short-term resting recordings (5-10 min) with age-matched non-cancer controls (Part A); long-term ambulatory recordings (12-30 h) were reported separately, and remaining studies synthesized narratively (Part B) or longitudinally (Part C). Certainty was assessed using GRADE (PROSPERO CRD42026130103).
resultsTwenty-eight studies (3232 participants; 9 cancer categories) were included; five met pooling criteria. Cancer patients showed lower SDNN (MD = -14.05 ms [95% CI -18.20, -9.90]), RMSSD (-16.76 ms [-21.23, -12.28]), and pNN50 (-6.05% [-9.36, -2.74]); all p < 0.001, I
conclusionsCancer patients show consistently suppressed short-term time-domain HRV, a clinically plausible signal of autonomic impairment. Because it aggregates mechanistically distinct sources (malignancy, cardiotoxicity, perioperative vagal withdrawal, survivorship remodeling), the pooled estimate cannot attribute suppression to any cause, and Very Low certainty precludes recommending HRV as an established clinical biomarker. Treatment-phase-stratified studies with standardized protocols and non-linear indices are needed.
Indexed as
Identifiers
42809037What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.